Healthcare Business Roundup: Supernus Gets FDA Approval, Aeterna Zentaris Gets Nasdaq Compliance

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Teva Pharmaceuticals (NYSE:TEVA) and Active Biotech’s (ATVBF.PK) Laquinimod performed well in a Phase IIa trial of patients suffering with moderate to severe Crohns disease. The medication had a “robust, early and consistent effect on remission” and in response rates compared with a placebo. In addition, Laquinimod was well-tolerated.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Supernus Pharmaceuticals (SUPN) spiked at the open but gave back the entire gain, even though it won FDA approval for its epilepsy treatment, Oxtellar XR, which is a once-daily extended release formulation of oxcarbazepine.

Nasdaq has notified Aeterna Zentaris (NASDAQ:AEZS) that it regains compliance with its minimum bid price rule. However, investors apparently took little notice.

Don’t Miss: Here’s Why Pharmaceutical Stocks are Rising Now.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business